LOS ANGELES, Nov. 29, 2024 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. (“Humacyte” or “the Company”) HUMA for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company’s securities between May 10, 2024, and October 17, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before January 17, 2025.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Humacyte failed to maintain good manufacturing practices including microbial testing at its Durham, North Carolina facility. The FDA’s review of the Company’s Biologic License Application (BLA) would be delayed while it fixed its manufacturing problems. Due to these issues, the Company faced risks of the FDA failing to approve acellular tissue engineered vessel (“ATEV”) for vascular trauma in a timely manner. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Humacyte, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
Office: 310-301-3335
View original content to download multimedia:https://www.prnewswire.com/news-releases/huma-investors-have-opportunity-to-lead-humacyte-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302318549.html
SOURCE The Schall Law Firm
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
